New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 25, 2014
11:08 EDTLXK, INFN, PBYI, NFLX, QLIK, DECK, INO, ANGI, CMG, MLNXOptions with decreasing implied volatility
Options with decreasing implied volatility: INO PBYI MLNX DECK INFN CMG QLIK LKX ANGI NFLX
News For INO;PBYI;MLNX;DECK;INFN;CMG;QLIK;LXK;ANGI;NFLX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 15, 2015
16:01 EDTNFLXOptions Update; May 15, 2015
iPath S&P 500 VIX Short-Term Futures down 20c to 20.06 Option volume leaders: AAPL BAC FB NFLX TWTR BABA CSCO TSLA MU GILD T MSFT AMZN MCD
13:01 EDTNFLXOn The Fly: Top stock stories at midday
Subscribe for More Information
11:46 EDTCMGEl Pollo Loco plummets after Q1 comparable restaurant sales growth slows
Subscribe for More Information
10:31 EDTNFLXNetflix volatility at low end of historic range as shares at all-time high
Netflix May weekly call option implied volatility is at 25, June is at 28, July is at 37; compared to its 90-day average of 36; suggesting decreasing near term price movement on reports of talks to enter China's online video market.
09:37 EDTNFLXActive equity options trading on open
Active equity options trading on open: AAPL TWTR TSLA NFLX FB
09:11 EDTNFLXOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Bsquare (BSQR), up 34.2%... Applied Materials (AMAT), up 3.2%. ALSO HIGHER: Trillium Therapeutics (TRIL), up 13% after being initiated with an Outperform at Oppenheimer... Pernix Therapeutics (PTX), up 7.4% after announcing FDA approval of Treximet for use in pediatric patients... Advaxis (ADXS), up 4.4% after being initiated with a Buy at Jefferies... Netflix (NFLX), up 3.3% following a Bloomberg report that the company is in talks to enter China's online video market... Inovalon (INOV), up 2.9% after being upgraded to Buy from Neutral at Goldman. DOWN AFTER EARNINGS: El Pollo LoCo (LOCO), down 12.8%... King Digital (KING), down 8.3%. ALSO LOWER: PlasmaTech (PTBI), down 5.4% after filing to sell 1.93M shares for selling stockholders... Paycom Software (PAYC), down 7% after 8M share Spot Secondary priced at $36.25... Keurig Green Mountain (GMCR), down 5.9% after Keurig Kold investor presentation... 3D Systems (DDD), down 2.4% after CFO transition... Celladon (CLDN), down 5.1% after the CEO says that the company is evaluating strategic options.
09:04 EDTNFLXNetflix poised to open at all-time high above $600 per share
Shares of Netflix (NFLX) are up more than 3% in pre-market trading to trade near $606 per share after Bloomberg reported that the company is in talks with Wasu Media Holding, a Chinese media company backed by Alibaba (BABA) Executive Chairman Jack Ma, and other Chinese companies about forming a partnership to bring its content to China.
05:55 EDTNFLXNetflix in talks to enter China's online video market, Bloomberg reports
Subscribe for More Information
May 14, 2015
16:19 EDTPBYIOn The Fly: Top stock stories for Thursday
Subscribe for More Information
12:49 EDTPBYIOn The Fly: Top stock stories at midday
The market opened higher amid lower than expected weekly jobless claims, data showing that producer prices fell rather than rose in April and a continued slide in the dollar against the euro. The Dow notched triple digit gains right out of the gate and the averages have moved in a narrow range in morning trading, albeit at near-record levels. ECONOMIC EVENTS: In the U.S., initial jobless claims fell 1K to 264K in the week ended May 9, versus expectations for 273K first-time claims. The weekly data brought the four week moving average to 271.75K, which marks its lowest level in 15 years. The Producer Price Index fell 0.4% in April, with the core PPI reading sliding 0.2%, which missed expectations for both the headline and core PPI figures to have grown 0.1%. After dropping 1.3% yesterday against the euro, the U.S. dollar slid another 0.4% earlier to about $1.14 per euro, bringing its decline to about 7% versus the euro in the past month. COMPANY NEWS: Shares of Avon Products (AVP) were volatile after "PTG Capital Partners" announced via a filing with the SEC that it has submitted an offer to the board of Avon proposing to acquire all of the company's outstanding stock, and outstanding options to acquire such shares, in a recommended cash tender offer at a price per share of $18.75. Shares of Avon spiked initially after the filing, were halted several times due to volatile trading, and came well off their earlier highs as investors questioned the validity of the firm making the purported offer. A source told Dow Jones that the company was treating the purported bid as a hoax and Avon told CNBC that it had no proof PTG exists and that it has not received any offer. Still, Avon remained up about 4% to trade near $6.92 per share in early afternoon trading. MAJOR MOVERS: Among the notable gainers was Russia's QIWI (QIWI), which jumped 12% after the company announced that it has entered into an agreement with Otkritie to acquire the Contact money transfer system and the Rapida payment processing system, which are "highly value accretive" acquisitions according to analysts at JPMorgan. Also higher was China's Ctrip.com (CTRP), which gained 10% and was upgraded at Stifel and Oppenheimer following the company's Q1 results. Among the noteworthy losers was Puma Biotechnology (PBYI), which dropped 18% after data on the company's neratinib drug was disclosed via an abstract for the company's upcoming presentation at the American Society of Clinical Oncology, or ASCO, meeting. Also lower following its earnings report was retailer Kohl's (KSS), which slid over 12%. INDEXES: Near midday, the Dow was up 170.23, or 0.94%, to 18,230.72, the Nasdaq was up 55.96, or 1.12%, to 5,037.65, and the S&P 500 was up 17.10, or 0.81%, to 2,115.58.
11:38 EDTNFLXNetflix has a small potential bullish pattern developing
On the daily chart there is a small potential bullish flag developing. The pattern won't become active unless there is a breakout above $585. The time until the pattern expires is likely by end of day tomorrow, meaning it could fail by time or price. If the pattern becomes active and completes, upside potential would be to the $625 to $630 area. A breakdown below the low of the flag portion of the pattern at $575 or lower would void the pattern.
10:09 EDTPBYIIncreasing equity options volume on open
Increasing equity options volume on open: ONTY CBRL PBYI GWW AXLL IEV KSS EXPR UEC JACK
09:39 EDTLXKLexmark upgraded to Hold from Sell at Cross Research
09:34 EDTNFLXActive equity options trading on open
Subscribe for More Information
09:22 EDTPBYIOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Perry Ellis (PERY), up 11.5%... Ctrip.com (CTRP), up 13.4%. ALSO HIGHER: AcelRx (ACRX), up 10.3% after being awarded contract worth up to $17M from Defense Dept to advance ARX-04... Oncothyreon (ONTY), up 16.9% after ASCO presentation data released... CYREN (CYRN), up 14.6% after announcing agreement with Dell.... Discovery Laboratories (DSCO), up 5.2% after Aerosurf shows positive Phase 2a data... Kate Spade (KATE), up 3.9% after being initiated with an Outperform at Wedbush. DOWN AFTER EARNINGS: Digital Ally (DGLY), down 16.4%... Kohl's (KSS), down 10.2%... VOXX (VOXX), down 8.1%... Cosi (COSI), down 7.3%. ALSO LOWER: Biotechnology (PBYI), down 15.1%% after Neratinib data published in ASCO abstract... Gevo (GEVO), down 10.7% after 4.3M share Spot Secondary priced at $4.00.
09:20 EDTPBYIPuma Biotechnology data look strong, says Leerink
Leerink says that after close examination, the data in Puma Biotechnology's ASCO abstract for neratinib's adjuvant study ExteNET look strong. The firm notes that unlike the HERA trial for Herceptin which enrolled only centrally confirmed HER2-positive breast cancer patients, approximately 80% of Puma's ExteNET patients were confirmed to be HER2+ upon central testing. When focusing on these patients, the magnitude of benefit for neratinib improved, Leerink says. It estimates disease free survival including ductal carcinoma in situ difference at two years to be 4.5%. The firm keeps an Outperform rating on Puma amid today's selloff.
08:09 EDTPBYIPuma Biotechnology volatility elevated into release of four abstracts
Subscribe for More Information
07:52 EDTPBYIPuma Biotechnology data positive, says RBC Capital
RBC Capital believes that the data on Puma's neratinib drug indicates that it has strong efficacy, and additional benefits compared with prior trials. The firm expects investors and medical professionals to have a greater appreciation of the drug's benefits once all of the data on the drug is presented at ASCO. RBC keeps a $285 price target and Outperform rating on the shares.
07:11 EDTPBYIOptions expected to be active
Subscribe for More Information
06:20 EDTNFLXStocks with implied volatility below IV index mean; LNKD NFLX
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use